Effect of continuously intravenously infused blinatumomab on peripheral T-cell counts during the first treatment cycle of MRD⁺ ALL patients. (A) Mean T-cell counts of 20 evaluable patients are shown at baseline, at the mean nadir of the initial redistribution, at the mean time point of 50% recovery to baseline, at the mean time point of maximal expansion, at the end of the 4-week treatment period, and at 1 week after the end of infusion. Error bars indicate SD for the respective cell counts and time points. Numbers of this graph are given in Table 2. (B) Statistical analysis of the initial T-cell redistribution observed during the first day, and (C) of the maximal T-cell expansion during blinatumomab infusion. Bars in the respective left subpanels give median values; brackets indicate P values. Individual patient correlations are shown in the respective right subpanels.